Erenumab
Aimovig (erenumab) is an antibody pharmaceutical. Erenumab was first approved as Aimovig on 2018-05-17. It has been approved in Europe to treat migraine disorders. It is known to target calcitonin gene-related peptide type 1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aimovig | Biologic Licensing Application | 2024-08-15 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
75 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | 7 | 5 | 9 | 18 | 20 | 59 |
| Headache | D006261 | HP_0002315 | R51 | 1 | 5 | — | 3 | 2 | 11 |
| Secondary headache disorders | D051271 | — | — | — | — | — | 1 | — | 1 |
| Prescription drug overuse | D000067490 | — | — | — | — | — | 1 | — | 1 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | — | — | 1 | — | 1 |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | — | — | 1 | — | 1 |
| Facial pain | D005157 | — | R51.9 | — | — | — | 1 | — | 1 |
| Facies | D019066 | — | — | — | — | — | 1 | — | 1 |
| Rhinosinusitis | D000096825 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | — | 1 | — | — | 1 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Post-traumatic headache | D051298 | — | G44.3 | — | 3 | — | — | — | 3 |
| Traumatic brain injuries | D000070642 | — | S06 | — | 2 | — | — | — | 2 |
| Brain concussion | D001924 | — | S06.0 | — | 2 | — | — | — | 2 |
| Brain injuries | D001930 | — | S06.9 | — | 2 | — | — | — | 2 |
| Neuralgia | D009437 | EFO_0009430 | — | — | 2 | — | — | — | 2 |
| Temporomandibular joint disorders | D013705 | — | M26.6 | — | 2 | — | — | — | 2 |
| Temporomandibular joint dysfunction syndrome | D013706 | — | — | — | 2 | — | — | — | 2 |
| Rosacea | D012393 | — | L71 | — | 1 | — | — | — | 1 |
| Flushing | D005483 | — | R23.2 | — | 1 | — | — | — | 1 |
| Post-concussion syndrome | D038223 | EFO_1001827 | F07.81 | — | 1 | — | — | — | 1 |
Show 15 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Hot flashes | D019584 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | — | — | — | 4 | 4 |
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | — | — | — | — | 2 | 2 |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | — | — | — | 1 | 1 |
| Interstitial cystitis | D018856 | EFO_1000869 | N30.1 | — | — | — | — | 1 | 1 |
| Syndrome | D013577 | — | — | — | — | — | — | 1 | 1 |
| Cystitis | D003556 | EFO_1000025 | N30 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Erenumab |
| INN | erenumab |
| Description | Erenumab, sold under the brand name Aimovig, is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine. It is administered by subcutaneous injection.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >6UMH:H,h|erenumab Fab heavy chain, IgG1
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLF
LQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDEVD
>6UMH:L,l|erenumab Fab light chain, IgG1
QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSTTLGITGLQ
TGDEADYYCGTWDSRLSAVVFGGGTKLTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVK
AGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS |
Identifiers
| PDB | 6UMG, 6UMH, 6UMI, 6UMJ |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3833329 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB14039 |
| UNII ID | I5I8VB78VT (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CALCRL
CALCRL
Organism
Homo sapiens
Gene name
CALCRL
Gene synonyms
CGRPR
NCBI Gene ID
Protein name
calcitonin gene-related peptide type 1 receptor
Protein synonyms
calcitonin receptor-like, Calcitonin receptor-like receptor, CGRP type 1 receptor
Uniprot ID
Mouse ortholog
Calcrl (54598)
calcitonin gene-related peptide type 1 receptor (Q9WUP2)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Aimovig – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,472 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
45,395 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use